JP7802018B2 - 経口製剤およびその用途 - Google Patents

経口製剤およびその用途

Info

Publication number
JP7802018B2
JP7802018B2 JP2022577703A JP2022577703A JP7802018B2 JP 7802018 B2 JP7802018 B2 JP 7802018B2 JP 2022577703 A JP2022577703 A JP 2022577703A JP 2022577703 A JP2022577703 A JP 2022577703A JP 7802018 B2 JP7802018 B2 JP 7802018B2
Authority
JP
Japan
Prior art keywords
compound
salt
meglumine salt
pharmaceutical composition
meglumine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022577703A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023532209A5 (https=
JP2023532209A (ja
Inventor
シン ダイ
シャオメイ ワン
ヤンチン リュー
ユエハン チアン
ヤオリン ワン
Original Assignee
インベンティスバイオ カンパニー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インベンティスバイオ カンパニー リミテッド filed Critical インベンティスバイオ カンパニー リミテッド
Publication of JP2023532209A publication Critical patent/JP2023532209A/ja
Publication of JP2023532209A5 publication Critical patent/JP2023532209A5/ja
Application granted granted Critical
Publication of JP7802018B2 publication Critical patent/JP7802018B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2022577703A 2020-06-19 2021-06-18 経口製剤およびその用途 Active JP7802018B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2020/097036 2020-06-19
PCT/CN2020/097036 WO2021253380A1 (en) 2020-06-19 2020-06-19 Oral formulations and uses thereof
PCT/CN2021/100806 WO2021254471A1 (en) 2020-06-19 2021-06-18 Oral formulations and uses thereof

Publications (3)

Publication Number Publication Date
JP2023532209A JP2023532209A (ja) 2023-07-27
JP2023532209A5 JP2023532209A5 (https=) 2024-06-18
JP7802018B2 true JP7802018B2 (ja) 2026-01-19

Family

ID=79268491

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022577703A Active JP7802018B2 (ja) 2020-06-19 2021-06-18 経口製剤およびその用途

Country Status (9)

Country Link
US (1) US20230263782A1 (https=)
EP (1) EP4168011B1 (https=)
JP (1) JP7802018B2 (https=)
KR (1) KR20230026415A (https=)
CN (1) CN115996723A (https=)
AU (1) AU2021291257A1 (https=)
CA (1) CA3179791A1 (https=)
MX (1) MX2022016118A (https=)
WO (2) WO2021253380A1 (https=)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004175795A (ja) 2002-11-13 2004-06-24 Takeda Chem Ind Ltd 薬物の放出性に優れた医薬組成物
JP2009529061A (ja) 2006-03-06 2009-08-13 ワイス 錠剤製剤およびプロセス
JP2013523833A (ja) 2010-04-07 2013-06-17 バーテックス ファーマシューティカルズ インコーポレイテッド ３−（６−（１−（２，２−ジフルオロベンゾ［ｄ］［１，３］ジオキソール−５−イル）シクロプロパンカルボキサミド）−３−メチルピリジン−２−イル）安息香酸の医薬組成物およびその投与
WO2018130124A1 (zh) 2017-01-11 2018-07-19 南京圣和药业股份有限公司 作为选择性雌激素受体下调剂的三环类化合物及其应用
JP2019504890A (ja) 2016-02-05 2019-02-21 インベンティスバイオ インコーポレイテッド 選択的エストロゲン受容体分解剤およびその使用
JP2020500168A (ja) 2016-10-24 2020-01-09 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー 分散性組成物
JP7448541B2 (ja) 2018-12-24 2024-03-12 インベンティスバイオ カンパニー リミテッド 選択的エストロゲン受容体分解剤の新規な塩

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY35590A (es) * 2013-05-28 2014-11-28 Astrazeneca Ab Nuevos compuestos para el tratamiento del cáncer
KR20220071293A (ko) * 2016-04-01 2022-05-31 리커리엄 아이피 홀딩스, 엘엘씨 에스트로겐 수용체 조절제
CN108864080B (zh) * 2017-05-09 2021-10-15 南京圣和药业股份有限公司 作为选择性雌激素受体下调剂的四环类化合物及其应用

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004175795A (ja) 2002-11-13 2004-06-24 Takeda Chem Ind Ltd 薬物の放出性に優れた医薬組成物
JP2009529061A (ja) 2006-03-06 2009-08-13 ワイス 錠剤製剤およびプロセス
JP2013523833A (ja) 2010-04-07 2013-06-17 バーテックス ファーマシューティカルズ インコーポレイテッド ３−（６−（１−（２，２−ジフルオロベンゾ［ｄ］［１，３］ジオキソール−５−イル）シクロプロパンカルボキサミド）−３−メチルピリジン−２−イル）安息香酸の医薬組成物およびその投与
JP2019504890A (ja) 2016-02-05 2019-02-21 インベンティスバイオ インコーポレイテッド 選択的エストロゲン受容体分解剤およびその使用
JP2020500168A (ja) 2016-10-24 2020-01-09 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー 分散性組成物
WO2018130124A1 (zh) 2017-01-11 2018-07-19 南京圣和药业股份有限公司 作为选择性雌激素受体下调剂的三环类化合物及其应用
JP7448541B2 (ja) 2018-12-24 2024-03-12 インベンティスバイオ カンパニー リミテッド 選択的エストロゲン受容体分解剤の新規な塩

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Organic Process Research & Development，2000年，Vol.4，pp.427-435，doi:10.1021/op000018u
薬剤学，2013年，Vol.73, No.3，pp.176-182

Also Published As

Publication number Publication date
EP4168011B1 (en) 2025-11-12
CN115996723A (zh) 2023-04-21
WO2021254471A1 (en) 2021-12-23
WO2021253380A1 (en) 2021-12-23
KR20230026415A (ko) 2023-02-24
AU2021291257A1 (en) 2023-01-19
EP4168011C0 (en) 2025-11-12
MX2022016118A (es) 2023-02-09
US20230263782A1 (en) 2023-08-24
EP4168011A4 (en) 2024-08-07
CA3179791A1 (en) 2021-12-23
JP2023532209A (ja) 2023-07-27
EP4168011A1 (en) 2023-04-26

Similar Documents

Publication Publication Date Title
JP7595672B2 (ja) 非晶質キナーゼ阻害剤の製剤およびその使用方法
JP6577143B2 (ja) ブルトンチロシンキナーゼの阻害剤を含む剤形組成物
US20070264330A1 (en) Pharmaceutical formulations of pimavanserin
CA3210612C (en) Formulations of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
EP3630726B1 (en) Crystalline solid forms of salts of n-{4-[(6,7-dimethoxyquinolin-4-yl) oxy]phenyl}-n'-(4-fluorphenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use
AU2025204843A1 (en) Compositions and methods for treatment of abnormal cell growth
CN110809471A (zh) 治疗特应性皮炎以及提高活性药物成分稳定性的制剂、方法、试剂盒和剂型
US20240343735A1 (en) Hydrochloride Salt of Inupadenant, Pharmaceutical Compositions and Methods of Use Thereof
KR20140129164A (ko) 히스톤 데아세틸라아제 억제제 및 파조파닙의 조합물 및 이의 용도
US11241418B2 (en) Salts of selective estrogen receptor degraders
JP2024539726A (ja) Ｎ－（（１ｒ，３ｓ）－３－（４－アセチルピペラジン－１－イル）シクロヘキシル）－４－フルオロ－７－メチル－１ｈ－インドール－２－カルボキサミドの結晶形態
JP7802018B2 (ja) 経口製剤およびその用途
TW202400141A (zh) ３－（（１ｒ，３ｒ）－１－（２，６－二氟－４－（（１－（３－氟丙基）四氫吖唉－３－基）胺基）苯基）－３－甲基－１，３，４，９－四氫－２ｈ－吡啶并［３，４－ｂ］吲哚－２－基）－２，２－二氟丙－１－醇酒石酸鹽之固體形式
HK40083383A (en) Oral formulations and uses thereof
US20250195487A1 (en) Formulations of a csf-1r inhibitor
WO2023280090A1 (zh) 一种药用组合物及其制备方法和用途
HK40126875A (zh) 奥比塞曲匹与依折麦布组合治疗和固定剂量药物组合物
WO2025092926A1 (zh) 一种嘧啶类衍生物的药物组合物
HK40026069A (en) Crystalline solid forms of salts of n-{4-[(6,7-dimethoxyquinolin-4-yl) oxy]phenyl}-n'-(4-fluorphenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use
HK40026069B (en) Crystalline solid forms of salts of n-{4-[(6,7-dimethoxyquinolin-4-yl) oxy]phenyl}-n'-(4-fluorphenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use
WO2016018380A1 (en) Steroid-free disease management

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20231215

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240610

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240610

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250609

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250619

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250918

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251216

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260106

R150 Certificate of patent or registration of utility model

Ref document number: 7802018

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150